Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

28 september 2026 bijgewerkt door: Incyte Corporation

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.

Studie Overzicht

Toestand

Nog niet aan het werven

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

24

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Incyte Corporation Call Center (US)
  • Telefoonnummer: 1.855.463.3463
  • E-mail: medinfo@incyte.com

Studie Contact Back-up

  • Naam: Incyte Corporation Call Center (ex-US)
  • Telefoonnummer: +800 00027423
  • E-mail: eumedinfo@incyte.com

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 85 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Ability to comprehend and willingness to sign a written ICF for the study.

  • Aged 18 to 85 years, inclusive, at the time of signing the ICF.

  • Severe renal impairment or ESRD based on CKD-EPI (National Kidney Foundation).

    • Participants with impaired renal function should have stable renal function (ie, those with acute changes in renal function should not be enrolled in the study).

  • Medical findings consistent with the degree of renal dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.

  • BMI of 18.0 to 43.0 kg/m2 (inclusive) at screening.

  • Ability to swallow and retain oral tablets.

  • Willingness to avoid pregnancy, breastfeeding, or fathering children.

Exclusion Criteria:

  • History of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.

    • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including but not limited to the following:
    • Recent myocardial infarction (within 6 months before check-in).
    • New York Heart Association Class III or IV congestive heart failure.
    • Unstable angina (within 6 months before check-in).
    • Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
    • Uncontrolled hypertension.
  • Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.

  • History of an autoimmune disease diagnosis (eg, myasthenia gravis).

  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at screening, confirmed by repeat testing).

  • Participants who have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.

  • Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).

  • History of malignancy within 5 years before screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.

  • Current or recent (within 3 months before screening) clinically significant GI disease or surgery (including cholecystectomy [< 2 months]; excluding appendectomy and hernia repair) that could affect the absorption of study drug.

  • Confirmed resting pulse rate (up to 2 consecutive measurements) < 40 bpm or > 100 bpm at screening.

  • Participants with laboratory values outside the accepted range for participants with severe renal impairment or ESRD at screening.

  • Any major surgery within 4 weeks before screening. Note: This does not include procedure for HD.

  • Blood transfusion within 4 weeks before check-in (Day -1).

  • Chronic or current active infectious disease (including latent tuberculosis) requiring systemic antibiotic, antifungal, or antiviral treatment.

  • Positive test result for HBV, HCV, or HIV. Upon testing, HBV DNA and HCV RNA must be undetectable.

    • Note 1: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive HBsAg antibody test as the only evidence of prior exposure may participate in the study.
    • Note 2: Participants who have cleared a prior HBV infection (defined as HbsAg negative, HBsAb positive, or HBcAb positive) may be included at the discretion of the investigator.
  • Receipt of any vaccine including but not limited to live (including attenuated), influenza, and SARS-CoV-2 vaccines within 3 months before the first dose of study drug.

  • Medical or self-reported history of alcoholism within 3 years before screening.

  • History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females, within 3 months before screening.

  • Treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug study.

  • Treatment within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program for prohibited drugs).

  • Active infection requiring systemic therapy.

  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.

  • Known hypersensitivity or severe reaction to INCB161734, any excipients of INCB161734, or any KRAS inhibitors (refer to the IB).

  • Inability to undergo venipuncture or tolerate venous access, or inadequate veins for repeat venipuncture or venous access as determined by the investigator.

  • Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.

  • Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days of study drug administration

    • Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
    • Note 2: Established therapy for renal disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration, is allowed if approved by the medical monitor and investigator.
  • Participants who are pregnant or lactating.

  • Excessive exercise (eg, Ironman, bi/triathlon) within 3 months before screening.

  • Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.

  • Participants who have a history of paracentesis within 3 months prior to check-in.

  • Participants who required new medication or an increase in dose for renal disease within 3 months prior to check-in.

  • Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor.

  • Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Group 1: Severe renal impairment

Participants with severe renal impairment will be enrolled in Group 1.

single dose administered orally

Experimenteel: Group 2: End-stage renal disease (ESRD)

Participants with end-stage renal disease will be enrolled in Group 2.

single dose administered orally

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PK for plasma INCB161734: Cmax
Tijdsspanne: Up to approximately 3.5 months

Defined as the maximum plasma concentration.

Up to approximately 3.5 months
PK for plasma INCB161734: AUClast
Tijdsspanne: Up to approximately 3.5 months

Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration.

Up to approximately 3.5 months
PK for plasma INCB161734: AUCinf
Tijdsspanne: Up to approximately 3.5 months

Defined as the area under concentration-time curve from time zero extrapolated to infinity.

Up to approximately 3.5 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Up to approximately 3.5 months and 30 days

Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug.

Up to approximately 3.5 months and 30 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Incyte Medical Monitor, Incyte Corporation

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

26 oktober 2026

Primaire voltooiing (Geschat)

30 maart 2027

Studie voltooiing (Geschat)

30 maart 2027

Studieregistratiedata

Eerst ingediend

28 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

28 september 2026

Eerst geplaatst (Werkelijk)

2 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

2 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

28 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren